TechCrunch · Note ·
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
What moved
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Why it matters
Filed as a public note from TechCrunch, 2026-09-23. Tagged Medical.
On the record
- Filed from the TechCrunch official RSS on 2026-09-23.
- Primary source host: techcrunch.com.
- The round valued the AI biotech at $2 billion.
Primary source
techcrunch.com
techcrunch.com
Desk
Logged as brief 188
Logged as brief 188